Nanobiotix S.A.
NNBXF
NNBXFNanobiotix S.A.
Other OTC9.10
USD
- -
- -
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Laurent Levy
- Full Time Employees
- 103
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 60 rue de Wattignies Paris France 75012
- IPO Date
- Jan 21, 2020
- Website
- nanobiotix.com
- Similar Companies
- Business
- Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Company News
Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript
Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript
Nanobiotix S.A. (NBTX) Q4 2023 Earnings Call Transcript
Nanobiotix S.A. (NBTX) Q3 2023 Earnings Call Transcript
Nanobiotix S.A. (NBTX) Q2 2023 Earnings Call Transcript
Nanobiotix S.A. (NBTX) Q4 2022 Earnings Call Transcript
Nanobiotix S.A. (NBTX) Q3 2022 Earnings Call Transcript
Nanobiotix S.A (NBTX) Q2 2022 Earnings Call Transcript
Nanobiotix's (NBTX) CEO Laurent Levy on Q1 2022 Results - Earnings Call Transcript
NANOBIOTIX Announces Pricing of Global Offering and Approval to List on NASDAQ Global Select Market
NANOBIOTIX Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Range